Do human leukocyte antigen-typed cellular therapeutics based on induced pluripotent stem cells make commercial sense?

Stem Cells and Development

Volumn 24, Issue 1, 2015, Pages 1-10

  Bravery, Christopher A ^a  

^a Advanced Biological Ltd Units 15 and 16   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; RECOMBINANT PROTEIN; HLA ANTIGEN;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD GROUP TYPING; CELL LINE; CELLS BY BODY ANATOMY; COMMERCIAL PHENOMENA; GOOD MANUFACTURING PRACTICE; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRODUCT DEVELOPMENT; REVIEW; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; CYTOLOGY; ECONOMICS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; PROCEDURES;

CELL LINE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84919797661     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0136     Document Type: Review

References (36)

1. Takahashi K and S Yamanaka. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.
2. Hanna J, M Wernig, S Markoulaki, CW Sun, A Meissner, JP Cassady, C Beard, T Brambrink, LC Wu, TM Townes and R Jaenisch. (2007). Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318:1920-1923.
3. Wilmut I, G Sullivan and I Chambers. (2011). The evolving biology of cell reprogramming. Philos Trans R Soc Lond B Biol Sci 366:2183-2197.
4. Mostoslavsky G. (2012). Concise review: the magic act of generating induced pluripotent stem cells: many rabbits in the hat. Stem Cells 30:28-32.
5. McKernan R and FM Watt. (2013). What is the point of large-scale collections of human induced pluripotent stem cells? Nat Biotech 31:875-877.
6. Puri MC and A Nagy. (2012). Concise review: embryonic stem cells versus induced pluripotent stem cells: the game is on. Stem Cells 30:10-14.
7. Prescott C. (2011). The business of exploiting induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci 366:2323-2328.
8. Taylor CJ, S Peacock, AN Chaudhry, JA Bradley and EM Bolton. (2012). Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 11:147-152.
9. Gourraud PA, L Gilson, M Girard and M Peschanski. (2012). The role of human leukocyte antigen matching in the development of multiethnic ''haplobank'' of induced pluripotent stem cell lines. Stem Cells 30:180-186.
10. Turner M, S Leslie, Nicholas G Martin, M Peschanski, M Rao, Craig J Taylor, A Trounson, D Turner, S Yamanaka and I Wilmut. (2013). Toward the Development of a Global Induced Pluripotent Stem Cell Library. Cell Stem Cell 13:382-384.
11. Umetsu DT, D Katzen, HH Jabara and RS Geha. (1986). Antigen presentation by human dermal fibroblasts: activation of resting T lymphocytes. J Immunol 136:440-445.
12. Phillips TJ, J Bhawan, IM Leigh, HJ Baum and BA Gilchrest. (1990). Cultured epidermal autografts and allografts: a study of differentiation and allograft survival. J Am Acad Dermatol 23:189-198.
13. Phillips TJ and BA Gilchrest. (1990). Cultured epidermal grafts in the treatment of leg ulcers. Adv Dermatol 5:33-48; discussion 49.
14. Syed BA and JB Evans. (2013). Stem cell therapy market. Nat Rev Drug Discov 12:185-186.
15. Opelz G, J Mytilineos, S Scherer, H Dunckley, J Trejaut, J Chapman, D Middleton, D Savage, O Fischer and JD Bignon. (1991). Survival of DNA HLA-DR typed and matched cadaver kidney transplants. The Collaborative Transplant Study. Lancet 338:461-463.
16. Takemoto SK, PI Terasaki, DW Gjertson and JM Cecka. (2000). Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 343:1078-1084.
17. Mackensen A, R Dräger, M Schlesier, R Mertelsmann and A Lindemann. (2000). Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 49:152-156.
18. Kadri N, N Potiron, M Ouary, D Jegou, E Gouin, JM Bach and B Lieubeau. (2007). Fetal calf serum-primed dendritic cells induce a strong anti-fetal calf serum immune response and diabetes protection in the non-obese diabetic mouse. Immunol Lett 108:129-136.
19. Hossler P, SF Khattak and ZJ Li. (2009). Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19:936-949.
20. Hidalgo A and PS Frenette. (2005). Enforced fucosylation of neonatal CD34 + cells generates selectin ligands that enhance the initial interactions with microvessels but not homing to bone marrow. Blood 105:567-575.
21. Sackstein R, JS Merzaban, DW Cain, NM Dagia, JA Spencer, CP Lin and R Wohlgemuth. (2008). Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 14:181-187.
22. Robinson SN, MW Thomas, PJ Simmons, et al. (2014). Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 16:84-89.
23. Bravery CA. (2010). Regulating interface science healthcare products: myths and uncertainties. J R Soc Interface 7 Suppl 6:S789-S795.
24. BSI. (2012). Developing human cells for clinical applications in the European Union and the United States of America. Guide. In: PAS 83:2012. BSI Standards Limited, London, United Kingdom.
25. Bravery CA. (2011). A CATalyst for change: regulating regenerative medicines in Europe. In: The Delivery of Regenerative Medicines and their impact on healthcare. Prescott CD and JM Polak eds. CRC, Boca Raton, FL, pp 295-322.
26. Grampp G and S Ramanan. (2013). Managing unexpected events in the manufacturing of biologic medicines. Bio-Drugs 27:305-316.
27. Placzek MR, IM Chung, HM Macedo, et al. (2009). Stem cell bioprocessing: fundamentals and principles. J R Soc Interface 6:209-232.
28. Williams DJ, RJ Thomas, PC Hourd, A Chandra, E Ratcliffe, Y Liu, EA Rayment and JR Archer. (2012). Precision manufacturing for clinical-quality regenerative medicines. Philos Trans A Math Phys Eng Sci 370:3924-3949.
29. ICH. (1995). Quality of biotechnological products: stability testing of biotechnological/biological products Q5C. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. www.ich.org
30. Boulting GL, E Kiskinis, GF Croft, et al. (2011). A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 29:279-286.
31. Dey E. (2010). Dendreon Inks Supply Deal with Glaxo on Cancer Vaccine. www.reuters.com. Reuters, London.
32. Scott C and B Huggett. (2012). Geron's quixotic fate. Nat Biotechnol 30:497.
33. Fu JD, NR Stone, L Liu, CI Spencer, L Qian, Y Hayashi, P Delgado-Olguin, S Ding, BG Bruneau and D Srivastava. (2013). Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Rep 1:235-247.
34. Wapinski OL, T Vierbuchen, K Qu, et al. (2013). Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. Cell 155:621-635.
35. Kaneko S and SYamanaka. (2013). To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell 12:385-386.
36. DiMasi JA, L Feldman, A Seckler and A Wilson. (2010). Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 87:272-277.